DE69619140D1 - Verbindungen die die retrovirale protease hemmen - Google Patents

Verbindungen die die retrovirale protease hemmen

Info

Publication number: DE69619140D1
Authority: DE; Germany
Prior art keywords: connections; retroviral protease; inhibit retroviral; inhibit; protease
Prior art date: 1995-12-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69619140T

Other languages

English (en)

Other versions

DE69619140T2 (de

Inventor

Leung Sham

W Norbeck

Xiaoqi Chen

A Betebenner

J Kempf

R Herrin

N Kumar

L Condon

J Cooper

A Dickman

M Hannick

Lawrence Kolaczkowski

A Oliver

J Plata

J Stengel

J Stoner

J Tien

Jih-Hua Liu

M Patel

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Abbott Laboratories

Original Assignee

Abbott Laboratories

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-13

Filing date

1996-12-06

Publication date

2002-03-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27075785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69619140(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-12-06 Application filed by Abbott Laboratories filed Critical Abbott Laboratories

2002-03-21 Publication of DE69619140D1 publication Critical patent/DE69619140D1/de

2002-10-31 Application granted granted Critical

2002-10-31 Publication of DE69619140T2 publication Critical patent/DE69619140T2/de

2016-12-07 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
- C07D207/408—Radicals containing only hydrogen and carbon atoms attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
- C07D223/10—Oxygen atoms attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/42—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/10—Oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Virology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
Biotechnology (AREA)
AIDS & HIV (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DE69619140T 1995-12-13 1996-12-06 Verbindungen die die retrovirale protease hemmen Expired - Lifetime DE69619140T2 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US57222695A	1995-12-13	1995-12-13
US08/753,201 US5914332A (en)	1995-12-13	1996-11-21	Retroviral protease inhibiting compounds
PCT/US1996/020440 WO1997021685A1 (en)	1995-12-13	1996-12-06	Retroviral protease inhibiting compounds

Publications (2)

Publication Number	Publication Date
DE69619140D1 true DE69619140D1 (de)	2002-03-21
DE69619140T2 DE69619140T2 (de)	2002-10-31

Family

ID=27075785

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69619140T Expired - Lifetime DE69619140T2 (de)	1995-12-13	1996-12-06	Verbindungen die die retrovirale protease hemmen

Country Status (20)

Country	Link
US (6)	US5914332A (de)
EP (2)	EP0882024B1 (de)
JP (4)	JP3170292B2 (de)
KR (2)	KR100404993B1 (de)
CN (1)	CN1207288C (de)
AR (2)	AR005053A1 (de)
AT (1)	ATE212986T1 (de)
AU (1)	AU725369C (de)
CA (3)	CA2509505A1 (de)
CO (1)	CO5070655A1 (de)
CZ (5)	CZ294246B6 (de)
DE (1)	DE69619140T2 (de)
DK (1)	DK0882024T3 (de)
ES (1)	ES2173341T3 (de)
HK (2)	HK1045303A1 (de)
HU (2)	HU222731B1 (de)
IL (6)	IL156236A0 (de)
NZ (4)	NZ326132A (de)
PT (1)	PT882024E (de)
WO (1)	WO1997021685A1 (de)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5914332A (en) *	1995-12-13	1999-06-22	Abbott Laboratories	Retroviral protease inhibiting compounds
US6232333B1 (en) *	1996-11-21	2001-05-15	Abbott Laboratories	Pharmaceutical composition
ZA9710071B (en) *	1996-11-21	1998-05-25	Abbott Lab	Pharmaceutical composition.
WO1999066936A1 (en) *	1998-06-24	1999-12-29	Emory University	Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
WO2000040558A1 (en) *	1999-01-06	2000-07-13	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Aspartic protease inhibitors
CA2371109C (en) *	1999-06-04	2011-04-26	Laman A. Alani	Improved pharmaceutical formulations
US7141593B1 (en) *	1999-06-04	2006-11-28	Abbott Laboratories	Pharmaceutical formulations
DE60028754T2 (de) *	1999-11-12	2007-05-31	Abbott Laboratories, Abbott Park	Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
US7364752B1 (en) *	1999-11-12	2008-04-29	Abbott Laboratories	Solid dispersion pharamaceutical formulations
ES2304990T3 (es)	2000-01-19	2008-11-01	Abbott Laboratories	Formulaciones farmaceuticas de inhibidores de la proteasa del vih mejoradas.
CA2404687A1 (en)	2000-03-30	2001-10-11	Nemichand B. Jain	Sustained release beadlets containing stavudine
MY128296A (en)	2000-03-30	2007-01-31	Abbott Lab	Crystalline pharmaceutical
US6608198B2 (en) *	2000-03-30	2003-08-19	Abbott Laboratories	Crystalline pharmaceutical
DE10026698A1 (de)	2000-05-30	2001-12-06	Basf Ag	Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US6372905B1 (en)	2000-08-31	2002-04-16	Abbott Laboratories	Processes and intermediates for preparing retroviral protease inhibitors
WO2002018349A2 (en) *	2000-08-31	2002-03-07	Abbott Laboratories	Process and intermediates for preparing retroviral protease inhibitors
US6911214B2 (en)	2000-09-05	2005-06-28	Abbott Laboratories	Flavoring systems for pharmaceutical compositions and methods of making such compositions
EP1387684A1 (de) *	2001-05-01	2004-02-11	Abbott Laboratories	Verbindungen enthaltend lopinavir und methoden zur erhöhung der bioverfügbarkeit pharmazeutischer stoffe
US20030138483A1 (en) *	2001-05-25	2003-07-24	Sergio Petriconi	Soft elastic capsules and compositions thereof
US7838046B2 (en) *	2001-09-26	2010-11-23	Tampa Bay Research Institute	Plant extracts and uses thereof
US6866875B2 (en) *	2001-09-26	2005-03-15	Tampa Bay Research Institute	Pine cone extracts and uses thereof
US20040197321A1 (en) *	2002-03-19	2004-10-07	Tibor Sipos	Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20030180279A1 (en) *	2002-03-19	2003-09-25	Tibor Sipos	Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20050239054A1 (en) *	2002-04-26	2005-10-27	Arimilli Murty N	Method and compositions for identifying anti-HIV therapeutic compounds
JP4942915B2 (ja) *	2002-04-26	2012-05-30	ギリアードサイエンシーズ，インコーポレイテッド	Ｈｉｖプロテアーゼ阻害剤化合物のホスホネートアナログの細胞蓄積
US7205413B2 (en) *	2002-05-03	2007-04-17	Transform Pharmaceuticals, Inc.	Solvates and polymorphs of ritonavir and methods of making and using the same
ITMI20021168A1 (it) *	2002-05-30	2003-12-01	Clariant Lsm Italia Spa	Procedimento per la preparazione dell'acido (s)-tetraidro-a-(1-metiletil)-2-osso-1(2h)-piridinacetico
US7300924B2 (en) *	2003-04-25	2007-11-27	Gilead Sciences, Inc.	Anti-infective phosphonate analogs
US20090247488A1 (en) *	2003-04-25	2009-10-01	Carina Cannizzaro	Anti-inflammatory phosphonate compounds
US7407965B2 (en) *	2003-04-25	2008-08-05	Gilead Sciences, Inc.	Phosphonate analogs for treating metabolic diseases
US7470724B2 (en) *	2003-04-25	2008-12-30	Gilead Sciences, Inc.	Phosphonate compounds having immuno-modulatory activity
CN101410120A (zh) *	2003-04-25	2009-04-15	吉里德科学公司	抗炎的膦酸酯化合物
US7427636B2 (en) *	2003-04-25	2008-09-23	Gilead Sciences, Inc.	Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
WO2005002626A2 (en) *	2003-04-25	2005-01-13	Gilead Sciences, Inc.	Therapeutic phosphonate compounds
CA2522845A1 (en) *	2003-04-25	2004-11-11	Gilead Sciences, Inc.	Kinase inhibitor phosphonate conjugates
EP1628685B1 (de)	2003-04-25	2010-12-08	Gilead Sciences, Inc.	Antivirale phosphonate analoge
US20050261237A1 (en) *	2003-04-25	2005-11-24	Boojamra Constantine G	Nucleoside phosphonate analogs
US7432261B2 (en) *	2003-04-25	2008-10-07	Gilead Sciences, Inc.	Anti-inflammatory phosphonate compounds
US7452901B2 (en) *	2003-04-25	2008-11-18	Gilead Sciences, Inc.	Anti-cancer phosphonate analogs
US20060148865A1 (en) *	2003-06-27	2006-07-06	Martin Michael T	Preparation of chemical compounds
US20050048112A1 (en)	2003-08-28	2005-03-03	Jorg Breitenbach	Solid pharmaceutical dosage form
US8377952B2 (en) *	2003-08-28	2013-02-19	Abbott Laboratories	Solid pharmaceutical dosage formulation
US8025899B2 (en)	2003-08-28	2011-09-27	Abbott Laboratories	Solid pharmaceutical dosage form
WO2005044279A1 (en) *	2003-10-24	2005-05-19	Gilead Sciences, Inc.	Purine nucleoside phosphonate conjugates
WO2005044308A1 (en) *	2003-10-24	2005-05-19	Gilead Sciences, Inc.	Phosphonate analogs of antimetabolites
CA2543294A1 (en) *	2003-10-24	2005-05-26	Gilead Sciences, Inc.	Methods and compositions for identifying therapeutic compounds
US20050131042A1 (en) *	2003-12-11	2005-06-16	Flentge Charles A.	HIV protease inhibiting compounds
US7834043B2 (en) *	2003-12-11	2010-11-16	Abbott Laboratories	HIV protease inhibiting compounds
US20050131017A1 (en) *	2003-12-11	2005-06-16	Degoey David A.	HIV protease inhibiting compounds
US8193227B2 (en)	2003-12-11	2012-06-05	Abbott Laboratories	HIV protease inhibiting compounds
EP1697348B1 (de) *	2003-12-11	2011-12-28	Abbott Laboratories	Die hiv-protease hemmende verbindungen
ATE539074T1 (de) *	2003-12-11	2012-01-15	Abbott Lab	Die hiv-protease hemmende verbindungen
BRPI0418031A (pt) *	2003-12-22	2007-04-17	Gilead Sciences Inc	inibidores de quinase fosfonato-substituìdos
US20050153990A1 (en) *	2003-12-22	2005-07-14	Watkins William J.	Phosphonate substituted kinase inhibitors
EP1706405B1 (de) *	2003-12-22	2009-03-04	Gilead Sciences, Inc.	4'-substituierte carbovir- und abacavir-derivate sowie verwandte verbindungen mit hiv- und hcv-antiviraler wirkung
ME01059B (me)	2003-12-23	2012-10-20	Janssen Sciences Ireland Uc	Proces za pripremanje (3r,3as,6ar)-heksahidrofuro [2,3-b] furan-3-il (1s,2r)-3-[[(4-aminofenil) sulfonil] (izobutil) amino]-1-benzil-2- hidroksipropilkarbamata
AU2003300167B2 (en) *	2003-12-31	2010-09-16	K-Pax Vitamins, Inc.	Nutrient compositions and methods for enhanced effectiveness of the immune system
BRPI0401742B8 (pt)	2004-05-13	2021-05-25	Cristalia Produtos Quim Farmaceuticos Ltda	composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
NZ590128A (en)	2004-07-06	2012-08-31	Abbott Lab	Prodrugs of HIV protease inhibitors
NZ553405A (en)	2004-07-27	2010-03-26	Gilead Sciences Inc	Nucleoside phosphonate conjugates as anti-HIV agents
US20060046969A1 (en) *	2004-08-25	2006-03-02	Aegis Therapeutics Llc	Antibacterial compositions for drug administration
US20060046962A1 (en) *	2004-08-25	2006-03-02	Aegis Therapeutics Llc	Absorption enhancers for drug administration
US8268791B2 (en) *	2004-08-25	2012-09-18	Aegis Therapeutics, Llc.	Alkylglycoside compositions for drug administration
US20140162965A1 (en)	2004-08-25	2014-06-12	Aegis Therapeutics, Inc.	Compositions for oral drug administration
EP2457580A1 (de) *	2004-08-25	2012-05-30	The UAB Research Foundation	Absorptionsverbesserer zur Arzneimittelverabreichung
US20090047347A1 (en) *	2005-07-29	2009-02-19	Aegis Therapeutics, Inc.	Compositions for Drug Administration
US9895444B2 (en)	2004-08-25	2018-02-20	Aegis Therapeutics, Llc	Compositions for drug administration
WO2006090264A1 (en) *	2005-02-28	2006-08-31	Ranbaxy Laboratories Limited	A process for the synthesis of 2-amino-5-protected amino-3-hydroxy-1, 6-diphenylhexane or a salt thereof - an intermediate for antiviral drugs
WO2006100552A1 (en) *	2005-02-28	2006-09-28	Ranbaxy Laboratories Limited	Processes for the preparation of lopinavir and its intermediate - (s)-tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2h)-pyrimidineacetic acid
CN101088991B (zh) *	2006-06-12	2013-05-22	浙江普洛医药科技有限公司	(s)-2-(2-羰基-四氢嘧啶-1(2h)-基)-3-甲基丁酸的制备方法
US8226949B2 (en)	2006-06-23	2012-07-24	Aegis Therapeutics Llc	Stabilizing alkylglycoside compositions and methods thereof
UY30535A1 (es) *	2006-08-10	2008-03-31	Cipla Ltd	Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones.
EP2112925A4 (de) *	2006-11-15	2013-01-09	Abbott Lab	Formulierungen mit fester pharmazeutischer dosierung
CN102816111B (zh)	2007-03-12	2014-08-06	尼克塔治疗公司	低聚物-蛋白酶抑制剂偶联物
FR2914920B1 (fr) *	2007-04-11	2011-09-09	Clariant Specialty Fine Chem F	Procede de deacetalisation d'alpha-aminoacetals.
NZ582089A (en) *	2007-06-29	2013-01-25	Gilead Sciences Inc	Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir
CA2692101A1 (en) *	2007-06-29	2009-01-08	Gilead Sciences, Inc.	Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and a compound that inhibits a ugt pathway or ugt metabolism
WO2009004653A2 (en) *	2007-07-04	2009-01-08	Matrix Laboratories Limited	Process for preparing an amorphous form of (2s,3s,5s)-2-(2,6- dimethylphenoxyacetyl)-amino-3-hydroxy-5-(2-(1-tetrahydropyrimid-2-only)-3-methylbutanoyl)-amino-1,6-diphenyl hexane and product thereof
US20110224435A1 (en) *	2007-08-07	2011-09-15	Ranbaxy Laboratories Limited	Process for preparation of amorphous lopinavir
CN101959506A (zh)	2008-02-28	2011-01-26	雅培制药有限公司	片剂和其制备方法
WO2009114151A1 (en)	2008-03-12	2009-09-17	Nektar Therapeutics	Oligomer-amino acid and olgomer-atazanavir conjugates
EP2271347B1 (de)	2008-03-28	2016-05-11	Hale Biopharma Ventures, Llc	Verabreichung von benzodiazepin-zusammensetzungen
US8658617B2 (en)	2008-07-08	2014-02-25	Gilead Sciences, Inc.	Salts of HIV inhibitor compounds
US20100021505A1 (en) *	2008-07-28	2010-01-28	Tibor Sipos	Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20100137235A1 (en) *	2008-10-15	2010-06-03	Mutual Pharmaceutical Company, Inc.	Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics
US8440631B2 (en)	2008-12-22	2013-05-14	Aegis Therapeutics, Llc	Compositions for drug administration
US7820681B1 (en)	2009-01-14	2010-10-26	Mutual Pharmaceutical Company, Inc.	Methods for concomitant administration of colchicine and a second active agent
WO2010089753A2 (en)	2009-02-06	2010-08-12	Hetero Research Foundation	Novel polymorphs of lopinavir
US20120108501A1 (en)	2009-06-12	2012-05-03	Nektar Therapeutics	Protease Inhibitors
US20110034489A1 (en) *	2009-07-31	2011-02-10	Ranbaxy Laboratories Limited	Solid dosage forms of hiv protease inhibitors
WO2011013110A1 (en)	2009-07-31	2011-02-03	Ranbaxy Laboratories Limited	Unit dosage forms of hiv protease inhibitors
WO2011094150A1 (en)	2010-01-27	2011-08-04	Glaxosmithkline Llc	Antiviral therapy
CN101967092A (zh) *	2010-07-02	2011-02-09	厦门市亨瑞生化有限公司	2,6-二甲基苯氧乙酸的合成方法
CN101967130B (zh) *	2010-07-02	2012-12-26	厦门市亨瑞生化有限公司	利托那韦中间体的合成方法
US9174944B1 (en)	2010-12-17	2015-11-03	Abbvie Inc.	Crystalline lopinavir/surfactant adducts
EP2683378A4 (de) *	2011-03-07	2014-09-03	Hetero Research Foundation	Amorphe form einer lopinavir- und ritonavirmischung
US9096556B2 (en)	2011-05-27	2015-08-04	Hetero Research Foundation	Amorphous ritonavir co-precipitated
WO2012174158A2 (en)	2011-06-14	2012-12-20	Hale Biopharma Ventures, Llc	Administration of benzodiazepine
US9040082B2 (en)	2011-06-24	2015-05-26	K-Pax Pharmaceuticals, Inc.	Compositions and methods for treatment of chronic fatigue
US20140288108A1 (en)	2011-11-28	2014-09-25	Ranbaxy Laboratories Limited	Process for the preparation of solid dispersion of lopinavir and ritonavir
JP6314131B2 (ja)	2012-05-03	2018-04-18	シプラ・リミテッド	抗レトロウイルス組成物
WO2014068265A1 (en)	2012-10-29	2014-05-08	Cipla Limited	Antiviral phosphonate analogues and process for preparation thereof
US9814235B2 (en)	2013-01-30	2017-11-14	Sumitomo Chemical Company, Limited	Method for controlling arthropod pest
CN103936679B (zh) *	2014-03-03	2016-05-11	厦门市亨瑞生化有限公司	一种2s—(1—四氢嘧啶—2—酮)—3—甲基丁酸的制备方法
WO2016069955A1 (en)	2014-10-29	2016-05-06	Wisconsin Alumni Research Foundation	Boronic acid inhibitors of hiv protease
RU2573991C1 (ru) *	2015-04-29	2016-01-27	Закрытое акционерное общество "ПЕПТЕК"	Способ получения n-ацетилглюкозаминил-n-ацетилмурамил-l-аланил-d-глутаминовой кислоты
WO2017059113A1 (en) *	2015-09-29	2017-04-06	Duke University	Compositions and methods for identifying and treating dystonia disorders
UA118192C2 (uk) *	2015-10-22	2018-12-10	Юрій Захарович Толчеєв	Противірусна фармацевтична композиція
WO2017141104A2 (en) *	2016-02-18	2017-08-24	Immune Therapeutics, Inc.	Method for inducing a sustained immune response
CN106117148B (zh) *	2016-06-17	2019-04-12	厦门市蔚嘉化学科技有限公司	一种洛匹那韦的制备和纯化工艺
CN106380412A (zh) *	2016-08-31	2017-02-08	中国科学院新疆生态与地理研究所	一种合成利托那韦中间体的方法
CN117899079A (zh)	2017-06-22	2024-04-19	希普拉有限公司	癌症的治疗方法
US10851125B2 (en)	2017-08-01	2020-12-01	Gilead Sciences, Inc.	Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate
CN107602454B (zh) *	2017-09-19	2020-12-01	佛山科学技术学院	磺酰胺类化合物及其制备方法和用途
JP2020031151A (ja) *	2018-08-23	2020-02-27	キオクシア株式会社	半導体記憶装置およびその製造方法
KR20200095934A (ko) *	2019-02-01	2020-08-11	재단법인 경기도경제과학진흥원	중동호흡기증후군 치료 또는 예방용 약학 조성물
US20230218644A1 (en)	2020-04-16	2023-07-13	Som Innovation Biotech, S.A.	Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN111393329A (zh) *	2020-04-16	2020-07-10	安徽一帆香料有限公司	一种利托那韦和洛匹那韦中间体的制备方法
CN112574027A (zh) *	2020-12-17	2021-03-30	盐城迪赛诺制药有限公司	一种2,6-二甲基苯氧基乙酸的生产工艺
WO2023118896A1 (en)	2021-12-23	2023-06-29	Subintro Limited	Novel antiviral compositions comprising oleic acid
CN115784936B (zh) *	2022-12-19	2023-12-26	启东东岳药业有限公司	一种利托那韦关键中间体bdh的制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3751262A (en) *	1970-06-30	1973-08-07	Allied Chem	Ruminant feed supplement
GB1539817A (en) *	1976-10-22	1979-02-07	Ucb Sa	N-substituted lactams
EP0005689B1 (de) *	1978-05-08	1981-03-18	U C B, S.A.	Lactam-N-Essigsäuren und ihre Amide, Verfahren zu ihrer Herstellung und Heilmittel, die sie enthalten
JPS54157586A (en) *	1978-05-30	1979-12-12	Toyama Chem Co Ltd	Penicillin and cephalosporin
US5142056A (en) *	1989-05-23	1992-08-25	Abbott Laboratories	Retroviral protease inhibiting compounds
US4448816A (en) *	1983-08-04	1984-05-15	The Upjohn Company	Compounds, compositions and process
US4885292A (en)	1986-02-03	1989-12-05	E. R. Squibb & Sons, Inc.	N-heterocyclic alcohol renin inhibitors
US5472946A (en) *	1988-04-08	1995-12-05	Peck; James V.	Transdermal penetration enhancers
IL90218A0 (en) *	1988-05-13	1989-12-15	Abbott Lab	Retroviral protease inhibitors
US5164388A (en) *	1988-10-19	1992-11-17	Abbott Laboratories	Heterocyclic peptide renin inhibitors
IL92011A0 (en) *	1988-10-19	1990-07-12	Abbott Lab	Heterocyclic peptide renin inhibitors
US5354866A (en) *	1989-05-23	1994-10-11	Abbott Laboratories	Retroviral protease inhibiting compounds
US5696270A (en) *	1989-05-23	1997-12-09	Abbott Laboratories	Intermediate for making retroviral protease inhibiting compounds
EP0428849A3 (en) *	1989-09-28	1991-07-31	Hoechst Aktiengesellschaft	Retroviral protease inhibitors
GB8927913D0 (en)	1989-12-11	1990-02-14	Hoffmann La Roche	Amino acid derivatives
DE69130070T2 (de)	1990-11-19	1999-04-29	Monsanto Co	Retrovirale protease inhibitoren
IE20010533A1 (en) *	1990-11-20	2003-03-05	Abbott Lab	Intermediates for preparing retroviral protease inhibiting compounds
CA2056911C (en)	1990-12-11	1998-09-22	Yuuichi Nagano	Hiv protease inhibitors
GB9111902D0 (en) *	1991-06-03	1991-07-24	Glaxo Group Ltd	Chemical compounds
EP0532466A3 (en)	1991-09-12	1993-06-16	Ciba-Geigy Ag	Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
US5643878A (en)	1991-09-12	1997-07-01	Ciba-Geigy Corporation	5-amino-4-hydroxyhexanoic acid derivatives
DE69232568T2 (de) *	1991-10-11	2002-12-19	Bristol Myers Squibb Pharma Co	Cyclische Harnstoffe und Analoga verwendbar als retrovirale Proteasehemmer
US5413999A (en)	1991-11-08	1995-05-09	Merck & Co., Inc.	HIV protease inhibitors useful for the treatment of AIDS
ES2066623T3 (es)	1992-03-13	1995-03-01	Bio Mega Boehringer Ingelheim	Derivados sustituidos del acido pipecolinico como inhibidores de la vih-proteasa.
DE4213659C2 (de) *	1992-04-25	1995-06-08	Koenig & Bauer Ag	Kurzfarbwerk für eine Rotationsdruckmaschine
AU676479B2 (en)	1992-05-20	1997-03-13	G.D. Searle & Co.	Method for making intermediates useful in synthesis of retroviral protease inhibitors
US5559256A (en) *	1992-07-20	1996-09-24	E. R. Squibb & Sons, Inc.	Aminediol protease inhibitors
IS2334B (is)	1992-09-08	2008-02-15	Vertex Pharmaceuticals Inc., (A Massachusetts Corporation)	Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
WO1994006775A1 (en)	1992-09-15	1994-03-31	Southern Research Institute	5,5-disubstituted hydantoins
US5484926A (en)	1993-10-07	1996-01-16	Agouron Pharmaceuticals, Inc.	HIV protease inhibitors
EP0674513B1 (de)	1992-12-29	1996-09-25	Abbott Laboratories	Inhibitoren der retroviralen protease
DE4318550A1 (de) *	1993-06-04	1994-12-08	Boehringer Mannheim Gmbh	Aryliden-4-oxo-2-thioxo-3- thiazolidincarbonsäuren, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5750648A (en)	1993-08-20	1998-05-12	G.D. Searle & Co.	Retroviral protease inhibitors and combinations thereof
IL110752A (en) *	1993-09-13	2000-07-26	Abbott Lab	Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5468733A (en) *	1993-09-30	1995-11-21	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5559158A (en) *	1993-10-01	1996-09-24	Abbott Laboratories	Pharmaceutical composition
US5770573A (en) *	1993-12-06	1998-06-23	Cytel Corporation	CS-1 peptidomimetics, compositions and methods of using the same
IL111991A (en) *	1994-01-28	2000-07-26	Abbott Lab	Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
JPH08151364A (ja)	1994-02-18	1996-06-11	Nissan Chem Ind Ltd	含窒素環状化合物および除草剤
IL129871A (en)	1994-05-06	2003-11-23	Pharmacia & Upjohn Inc	Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
AU3150395A (en) *	1994-08-09	1996-03-07	Abbott Laboratories	Retroviral protease inhibiting 1,2,4-triazacycloheptanes
US6037157A (en)	1995-06-29	2000-03-14	Abbott Laboratories	Method for improving pharmacokinetics
WO1997017180A1 (en)	1995-11-07	1997-05-15	Lonza Inc.	Halohydantoin forms and method by melt extrusion
US5914332A (en)	1995-12-13	1999-06-22	Abbott Laboratories	Retroviral protease inhibiting compounds
US5883252A (en) *	1996-01-26	1999-03-16	Vertex Pharmaceuticals Incorporated	Aspartyl protease inhibitors
FR2773994B1 (fr)	1998-01-23	2002-10-11	Univ Nice Sophia Antipolis	Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central
WO2000040558A1 (en) *	1999-01-06	2000-07-13	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Aspartic protease inhibitors

1996
- 1996-11-21 US US08/753,201 patent/US5914332A/en not_active Expired - Lifetime
- 1996-12-06 NZ NZ326132A patent/NZ326132A/xx not_active IP Right Cessation
- 1996-12-06 NZ NZ510328A patent/NZ510328A/en not_active IP Right Cessation
- 1996-12-06 DK DK96944941T patent/DK0882024T3/da active
- 1996-12-06 EP EP96944941A patent/EP0882024B1/de not_active Expired - Lifetime
- 1996-12-06 CA CA002509505A patent/CA2509505A1/en not_active Abandoned
- 1996-12-06 PT PT96944941T patent/PT882024E/pt unknown
- 1996-12-06 IL IL15623696A patent/IL156236A0/xx active IP Right Grant
- 1996-12-06 IL IL12460796A patent/IL124607A0/xx not_active IP Right Cessation
- 1996-12-06 CZ CZ19981762A patent/CZ294246B6/cs not_active IP Right Cessation
- 1996-12-06 CZ CZ20040762A patent/CZ296915B6/cs not_active IP Right Cessation
- 1996-12-06 ES ES96944941T patent/ES2173341T3/es not_active Expired - Lifetime
- 1996-12-06 IL IL15623796A patent/IL156237A/xx not_active IP Right Cessation
- 1996-12-06 AU AU13422/97A patent/AU725369C/en not_active Expired
- 1996-12-06 NZ NZ510329A patent/NZ510329A/xx not_active IP Right Cessation
- 1996-12-06 HU HU0003305A patent/HU222731B1/hu active IP Right Grant
- 1996-12-06 KR KR10-1998-0704560A patent/KR100404993B1/ko not_active IP Right Cessation
- 1996-12-06 KR KR10-2000-7010425A patent/KR100418316B1/ko not_active IP Right Cessation
- 1996-12-06 EP EP01124290A patent/EP1170289A3/de not_active Withdrawn
- 1996-12-06 HU HU9901079A patent/HU223782B1/hu active IP Right Grant
- 1996-12-06 CZ CZ20002210A patent/CZ293650B6/cs not_active IP Right Cessation
- 1996-12-06 AT AT96944941T patent/ATE212986T1/de active
- 1996-12-06 JP JP52227897A patent/JP3170292B2/ja not_active Expired - Lifetime
- 1996-12-06 IL IL13666196A patent/IL136661A0/xx not_active IP Right Cessation
- 1996-12-06 CZ CZ20014529A patent/CZ300127B6/cs not_active IP Right Cessation
- 1996-12-06 CA CA002285119A patent/CA2285119C/en not_active Expired - Lifetime
- 1996-12-06 NZ NZ338003A patent/NZ338003A/en not_active IP Right Cessation
- 1996-12-06 WO PCT/US1996/020440 patent/WO1997021685A1/en active IP Right Grant
- 1996-12-06 CN CNB961999047A patent/CN1207288C/zh not_active Expired - Lifetime
- 1996-12-06 DE DE69619140T patent/DE69619140T2/de not_active Expired - Lifetime
- 1996-12-06 CA CA002238978A patent/CA2238978C/en not_active Expired - Lifetime
- 1996-12-06 CZ CZ20014528A patent/CZ300131B6/cs not_active IP Right Cessation
- 1996-12-12 AR ARP960105646A patent/AR005053A1/es active IP Right Grant
- 1996-12-12 CO CO96065280A patent/CO5070655A1/es not_active Application Discontinuation
1998
- 1998-12-08 US US09/207,873 patent/US6284767B1/en not_active Expired - Lifetime
1999
- 1999-04-09 HK HK02105035.4A patent/HK1045303A1/zh unknown
- 1999-04-09 HK HK99101462A patent/HK1016585A1/xx not_active IP Right Cessation
2000
- 2000-02-23 US US09/511,390 patent/US6313296B1/en not_active Expired - Lifetime
- 2000-06-26 JP JP2000190510A patent/JP4181291B2/ja not_active Expired - Lifetime
- 2000-08-23 AR ARP000104345A patent/AR025352A1/es unknown
2001
- 2001-04-18 US US09/837,280 patent/US6472529B2/en not_active Expired - Lifetime
2002
- 2002-10-25 US US10/280,652 patent/US7279582B2/en not_active Expired - Lifetime
2003
- 2003-06-01 IL IL156236A patent/IL156236A/en not_active IP Right Cessation
2006
- 2006-02-27 IL IL173966A patent/IL173966A/en not_active IP Right Cessation
2007
- 2007-02-27 US US11/679,227 patent/US7968707B2/en not_active Expired - Fee Related
- 2007-12-19 JP JP2007327351A patent/JP5264160B2/ja not_active Expired - Lifetime
2012
- 2012-11-07 JP JP2012245536A patent/JP5597689B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CN1207288C (zh)	2005-06-22
JP4181291B2 (ja)	2008-11-12
IL124607A0 (en)	1998-12-06
IL156236A (en)	2006-10-31
US5914332A (en)	1999-06-22
IL156237A (en)	2005-05-17
AR025352A1 (es)	2002-11-20
IL173966A (en)	2012-02-29
JP2001058979A (ja)	2001-03-06
CZ176298A3 (cs)	1998-11-11
JP5264160B2 (ja)	2013-08-14
EP0882024B1 (de)	2002-02-06
US6284767B1 (en)	2001-09-04
HU223782B1 (hu)	2005-01-28
IL173966A0 (en)	2006-07-05
CA2238978A1 (en)	1997-06-19
NZ510328A (en)	2005-01-28
HK1045303A1 (zh)	2002-11-22
CZ300131B6 (cs)	2009-02-18
HK1016585A1 (en)	1999-11-05
JP2013047266A (ja)	2013-03-07
KR100418316B1 (ko)	2004-02-11
CA2285119A1 (en)	1997-06-19
CO5070655A1 (es)	2001-08-28
KR19990072195A (ko)	1999-09-27
AR005053A1 (es)	1999-04-07
JP3170292B2 (ja)	2001-05-28
US20030100755A1 (en)	2003-05-29
PT882024E (pt)	2002-07-31
HUP0003305A3 (en)	2000-12-28
US20020004503A1 (en)	2002-01-10
US20080139811A1 (en)	2008-06-12
NZ326132A (en)	1999-11-29
AU725369C (en)	2003-04-10
IL156237A0 (en)	2004-01-04
DE69619140T2 (de)	2002-10-31
KR100404993B1 (ko)	2004-06-04
JP2008115189A (ja)	2008-05-22
CN1208405A (zh)	1999-02-17
CA2238978C (en)	2001-05-15
CZ300127B6 (cs)	2009-02-18
IL156236A0 (en)	2004-01-04
HU222731B1 (hu)	2003-09-29
EP1170289A2 (de)	2002-01-09
ATE212986T1 (de)	2002-02-15
MX9804734A (es)	1998-10-31
CZ296915B6 (cs)	2006-07-12
CA2285119C (en)	2005-09-20
US6313296B1 (en)	2001-11-06
NZ338003A (en)	2005-08-26
EP0882024A1 (de)	1998-12-09
US7279582B2 (en)	2007-10-09
CZ294246B6 (cs)	2004-11-10
JP5597689B2 (ja)	2014-10-01
HUP9901079A2 (hu)	1999-09-28
AU725369B2 (en)	2000-10-12
AU1342297A (en)	1997-07-03
WO1997021685A1 (en)	1997-06-19
US6472529B2 (en)	2002-10-29
EP1170289A3 (de)	2002-11-13
DK0882024T3 (da)	2002-05-21
CZ293650B6 (cs)	2004-06-16
ES2173341T3 (es)	2002-10-16
JP2000502085A (ja)	2000-02-22
IL136661A0 (en)	2001-06-14
US7968707B2 (en)	2011-06-28
CA2509505A1 (en)	1997-06-19
HUP9901079A3 (en)	2000-08-28
NZ510329A (en)	2004-02-27

Legal Events

Date	Code	Title	Description
2003-03-06	8364	No opposition during term of opposition

Publication	Publication Date	Title
DE69619140T2 (de)	2002-10-31	Verbindungen die die retrovirale protease hemmen
DE69528825D1 (de)	2002-12-19	Dendrime verbindungen
DE69636353D1 (de)	2006-08-24	Datenübetragungsvorrichtung.
NL1004863A1 (nl)	1997-07-02	5-Amino-4-ethylsulfinyl-1-arylpyrazolen.
DE69518667T2 (de)	2001-04-19	Antiinflammatorische verbindungen
ATE254628T1 (de)	2003-12-15	Meiose regulierende verbindungen.
DE69610844T2 (de)	2001-03-29	Hydroformylierungsverfahren.
DE69716094D1 (de)	2002-11-07	Bromotiacumicin verbindungen
NL1000095C2 (nl)	1996-10-11	Rolhor.
KR960038721U (ko)	1996-12-18	반도체 몰드 다이
KR960028476U (ko)	1996-09-17	펀치
ES1031606Y (es)	1997-01-01	Estuche.
ES1031424Y (es)	1996-06-01	Estuche.
ITLE950006V0 (it)	1995-06-12	Double-band.
IT1276501B1 (it)	1997-10-31	Via tranviaria.
ES1030500Y (es)	1996-07-01	Braga-compresa monouso.
ES1033612Y (es)	1997-03-01	Octocarton.
ES1030760Y (es)	1996-03-16	Tocado-postizo.
ES1031849Y (es)	1996-07-01	Tapon-grifo.
IT239292Y1 (it)	2001-02-26	Volter.
IT240242Y1 (it)	2001-03-26	Pentola-colapasta-zuppiera.
ES1030262Y (es)	1996-03-01	Porta-objetos.
ES1030124Y (es)	1996-01-16	Bloc-pizarra.
ES1029950Y (es)	1996-01-01	Interruptor-conmutador.
ES1032568Y (es)	1996-11-01	Protector-precinto.